Icatibant Auxilia

Icatibant, the active ingredient in Icatibant Auxilia, is a bradykinin B2 receptor antagonist presented as an injection solution for subcutaneous use. It treats acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency.

GNH USA supplies Icatibant Auxilia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant acts on the bradykinin pathway to manage hereditary angioedema attacks.

Acute hereditary angioedema (C1‑inhibitor deficiency): rapid reduction of swelling and pain. Hereditary angioedema type I: blocks bradykinin‑mediated vasodilation. Hereditary angioedema type II: decreases vascular permeability.

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic exposure.

Common Side Effects: - Injection site pain: discomfort at the site of subcutaneous administration. - Redness or erythema: localized skin irritation. - Swelling at injection site: mild edema around the needle entry. - Nausea: transient gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: temporary light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure. - Angioedema of other regions: swelling beyond the treated area. - Urticaria: widespread hives. - Thrombocytopenia: low platelet count. - Severe allergic reaction: includes bronchospasm or laryngeal edema.

Before using Icatibant, consider the following safety measures.

Pregnancy: safety not established; use only if benefit outweighs risk. Breastfeeding: unknown safety; evaluate potential risks. Renal impairment: use with caution; monitor renal function. Concomitant ACE inhibitors: monitor for increased bradykinin‑related effects. History of hypersensitivity: avoid if previous reaction to icatibant. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medications that influence the bradykinin system or cardiovascular function.

Major Interactions (Avoid): - ACE inhibitors: additive bradykinin effect may increase angioedema risk. - Angiotensin receptor blockers: similar risk of enhanced bradykinin activity. - Other bradykinin B2 antagonists: no additive benefit and may raise adverse‑event likelihood.

Moderate Interactions (Monitor Closely): - Diuretics: monitor blood pressure for additive hypotensive effect. - NSAIDs: may increase risk of edema. - Estrogen‑containing contraceptives: may affect frequency of HAE attacks.